Flow cytometric analysis of human CD319 expression on human PBMC. Human PBMC were stained with Brilliant Violet 421™ Mouse Anti-Human CD3 Antibody and either FITC Mouse IgG2b, k Isotype Control (left panel) or SDT FITC Mouse Anti-Human CD319 Antibody (right panel) at 5 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
FITC Mouse Anti-Human CD319 Antibody (S-3010)
FITC Mouse Anti-Human CD319 Antibody (S-3010)
Price:
Regular price
$165 USD
Regular price
Sale price
$165 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD319 |
| Synonyms | SLAM family member 7; CD2 subset 1; CD2-like receptor-activating cytotoxic cells (CRACC); Membrane protein FOAP-12; Novel Ly9; Protein 19A; CS1; SLAMF7 |
| Location | Membrane |
| Accession | Q9NQ25 |
| Clone Number | S-3010 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2b,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | FITC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD319, also termed SLAMF7 or CS1, is a 66 kDa self-ligating type-I trans-membrane glycoprotein of the CD2/SLAM immunoglobulin superfamily that is constitutively expressed on NK cells, activated B cells, monocytes and, at very high levels, on multiple-myeloma cells; its cytoplasmic tail contains ITSM sequences that, depending on the simultaneous presence or absence of the adaptor proteins EAT-2 and SAP, can switch between activating (via PI3K-PLCγ-ERK) and inhibitory signaling, thereby modulating NK-cell cytotoxicity, B-cell proliferation, macrophage cytokine release and antibody-dependent myeloma killing, making it both an immunomodulatory receptor and the therapeutic target of the FDA-approved monoclonal antibody elotuzumab.
Picture
Picture
FC
